GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alector Inc (NAS:ALEC) » Definitions » YoY EPS Growth

ALEC (Alector) YoY EPS Growth : 18.87% (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Alector YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Alector's YoY EPS Growth for the quarter that ended in Sep. 2024 was 18.87%.

Alector's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was $-0.43.

Alector YoY EPS Growth Historical Data

The historical data trend for Alector's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alector YoY EPS Growth Chart

Alector Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
Get a 7-Day Free Trial -123.82 -43.27 81.63 -260.00 3.70

Alector Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.36 22.22 30.91 -2,100.00 18.87

Alector YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Alector's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-1.56--1.62)/ | -1.62 |
=3.70 %

Alector's YoY EPS Growth for the quarter that ended in Sep. 2024 is calculated as:

YoY EPS Growth (Q: Sep. 2024 )
=(Earnings per Share (Diluted) (Q: Sep. 2024 )-Earnings per Share (Diluted) (Q: Sep. 2023 )) / | Earnings per Share (Diluted) (Q: Sep. 2023 )) |
=(-0.43--0.53)/ | -0.53 |
=18.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alector YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Alector's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Alector Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alector Inc (NAS:ALEC) » Definitions » YoY EPS Growth
Comparable Companies
EWTX ANTX ANAB TSHA DYN FDMT LYEL AVXL TARS LQDA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
0Z2:Germany
Address
131 Oyster Point Boulevard, Suite 600, South San Francisco, CA, USA, 94080
Website
https://www.alector.com
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Executives
Sara Kenkare-mitra officer: President and Head of R&D C/O ALECTOR, INC, 131 OYSTER POINT BLVD, SUITE 600, SOUTH SAN FRANCISCO CA 94080
Gary Romano officer: Chief Medical Officer TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Arnon Rosenthal director, officer: Chief Executive Officer C/O ALECTOR, INC., 151 OYSTER POINT BLVD., #300, SOUTH SAN FRANCISCO CA 94080
Marc Grasso officer: Chief Financial Officer C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO CA 92121
Richard H Scheller director C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Paula Hammond director C/O ALECTOR, INC., 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA 94080
Kristine Yaffe director C/O ALECTOR, INC., 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO CA 94080
Polaris Venture Management Co. Vi, L.l.c. 10 percent owner ONE MARINA PARK DRIVE, 8TH FLOOR, BOSTON MA 02210
Terrance Mcguire director, 10 percent owner C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
Elizabeth A. Garofalo director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
David M. Wehner director C/O FACEBOOK, INC., 1601 WILLOW ROAD, MENLO PARK CA 94025
Tillman U. Gerngross director C/O ARSANIS, INC., 890 WINTER STREET, SUITE 230, WALTHAM MA 02451
Lavigne Louis J Jr director C/O ALLERGAN, INC., 2525 DUPONT DRIVE, IRVINE CA 92612
Robert King officer: Chief Development Officer 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Shehnaaz Suliman officer: President and COO 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080